source
- Eli Lilly beats forecasts with 56% revenue jump, lifts full-year outlookEli Lilly reported first‑quarter revenue of $19.8 billion, up 56% year over year, and net income of $7.4 billion, or $8.26 a share. Non‑GAAP earnings were $8.55 a share, well above the $6.77 consen…
- Merck remains optimistic on Terns leukemia drug despite new dataMerck said Thursday that it still sees a compelling outlook for Terns' leukemia drug even after updated study data suggested it may be less differentiated. The updated data came from a trial of TE…